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There is accumulating evidence indicating that endothelial factors are involved in the pathogenesis of GVHD.
We have recently shown that steroid-refractory, but not sensitive, GVHD is characterized by higher pre-
transplantation serum levels of angiopoetin-2 (ANG2), a hormone mediating endothelial vulnerability. To
evaluate whether endothelial vulnerability is a risk factor for GVHD per se or becomes important only when
noticeable GVHD is established, we measured ANG2 along with additional serum markers of endothelial
stress, including soluble thrombomodulin (sTM), IL-8 (CXCL8), and hepatocyte growth factor (HGF), in
patients with no, low-grade, or severe GVHD. Patients with refractory GVHD exhibited elevated serum levels
of ANG2, sTM, HGF, and IL-8 posttransplantation compared with patients with sensitive GVHD and patients
without GVHD. Pretransplantation ANG2 was the only growth factor correlated with the risk of refractoriness
and mortality, and then only within the subset of patients who developed grade III-IV GVHD. In contrast,
ANG2 was not predictive of GVHD or nonrelapse mortality (NRM) in patients with no GVHD or low-grade
GVHD. These ﬁndings provide evidence that endothelial function plays an important role in the pathogen-
esis of steroid refractoriness in ongoing GVHD; however, endothelial vulnerability does not predict incidence
of GVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION that the foregoing study focused solely onpatientswith acute
The curative potential of allogeneic stem cell trans-
plantation (allo-SCT) for hematopoietic malignancies depends
on immunologic recognition of malignant cells, a reaction
known as the graft-versus-leukemia effect [1]. However,
acute immune reactions transgressing from hematopoietic
tissue to skin, liver, and gut occur in up to 40% of recipients [2].
Although this graft-versus-hostdisease (GVHD) often responds
to escalated immunosuppressive therapy, a substantial
proportion of patients, particularly those with severe acute
intestinal GVHD, are refractory to even high-dose steroid
therapy. These steroid-refractorypatients generally have apoor
prognosis despite intensive salvage immunosuppression [3-7].
Why do steroid-refractory patients not respond to
immunosuppressive therapy? In addressing this question,we
have recently provided evidence indicating that differences in
endothelial vulnerability rather than differences in immune
activation are critical for the development of GVHD refractory
to high-dose steroids [8,9]. Before allo-SCT, steroid-refractory
patients, but not steroid-sensitive patients, had increased
levels of the endothelial vulnerability marker angiopoietin-2
(ANG2), followed by progressive endothelial damage as
measured by soluble thrombomodulin (sTM) level [9]. Givenedgments on page 27.
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12.09.018intestinal GVHD,whether pretransplantation ANG2 elevation
is predictive of GVHD risk and severity per se or is prognos-
tically relevantonly if aGVHDepisodeoccurs remainsunclear.
To address this question and to support our previous
ﬁndings, we analyzed an extended cohort of patients (n ¼
404) who underwent allogeneic stem cell transplantation. In
this study, along with the patients from our previous study,
we included patients with no GVHD as well as those with
low-grade GVHD, along with additional markers of endo-
thelial stress, including the chemokine IL-8 (CXCL8) and
hepatocyte growth factor (HGF), which have been correlated
with nonrelapse mortality (NRM) and occurrence of GVHD
[10-13]. Our ﬁndings suggest that pretransplantation eleva-
tion of markers of endothelial vulnerability is not correlated
with the risk of GVHD per se but is predictive of refractori-
ness in patients who later experience severe acute GVHD.
PATIENTS AND METHODS
Patient Eligibility
Patients who had undergone allo-SCT at our institution between
September 2001 and August 2010 and had available blood samples collected
longitudinally before and after transplantation were eligible for this study.
Written informed consent according to the Declaration of Helsinki was
obtained for all eligible patients. Our local Ethics Committee approved the
sample and data collection procedures. A total of 404 patients were
included. Serum samples obtained before allo-SCT were available for 331
patients, samples obtained at day 50 after allo-SCT were available for 297
patients, and samples obtained at day 100 after allo-SCT were available for
300 patients.Transplantation.
Table 1
Patient Characteristics by Maximum GVHD Grade and Steroid Response
Characteristic Group 1, No
GVHD (n ¼ 227)
Group 2, Grade I-II
GVHD (n ¼ 98)
Group 3, Grade III-IV
Sensitive GVHD (n ¼ 35)
Group 4, Grade III-IV
Refractory GVHD (n ¼ 44)
P Value
Age at allo-SCT, years, median (range) 52 (18-70) 52 (17-70) 46 (24-68) 50 (19-70) <.83
Sex, % <.68
Female 41 36 37 34
Male 59 64 63 66
Time to GVHD, months, median (95% CI) 1.3 (1.1-1.5) 1.0 (0.9-1.9) 1.1 (0.9-2.5) <.80
Donor, % <.003
Related donor 36 35 60 38
Matched unrelated donor 44 41 17 23
Mismatched unrelated donor 20 24 23 39
Donorerecipient sex mismatch <.12
Maleemale, femaleefemale 57 58 63 61
Maleefemale 26 23 23 16
Femaleemale 17 19 14 23
Disease, % <.11
Acute myelogenous leukemia, myelodysplastic
syndrome
39 35 32 50
Myeloproliferative syndrome 11 6 11 7
Acute lymphoblastic leukemia 10 10 11 9
Lymphoma, chronic lymphocytic leukemia 25 22 23 18
Multiple myeloma, amyloidosis 12 27 23 16
Aplastic anemia, paroxysmal nocturnal
hemoglobinuria
3
Disease score before allo-SCT [29], % <.11
0 30 28 26 32
1 12 10 23 18
2 50 60 48 50
Not available 8 2 3 0
Stem cell source, % <.88
Peripheral blood 93 93 96 95
Bone marrow 7 7 4 5
Conditioning, % <.26
Reduced intensity 71 72 57 64
Myeloablative 29 28 43 36
GVHD site, %
Skin 83 34 51 <.0001
Gut 29 85 91 <.0001
Liver 7 15 30 <.003
Percentages were calculated based on the number of patients in each GVHD group. P values were calculated for comparisons of all listed groups using the
Kruskal-Wallis test.
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GVHD was clinically and histologically diagnosed and graded using
standard criteria [14]. GVHD prophylaxis consisted of antithymocyte glob-
ulin with unrelated donors only; methotrexate 10 mg on days 1, 3, and 6 or,
in the event of contraindications for methotrexate, mycophenolate mofetil
2  1 g/day on days 1-28; and cyclosporin A. Cyclosporin A was replaced by
tacrolimus if the patient experienced toxic side effects. Prednisolone (1-2
mg/kg) was the ﬁrst-line therapy for acute GVHD in all patients. In the event
of acute gastrointestinal GVHD, steroids were combined with mycopheno-
late mofetil 2  1 g/day for ﬁrst-line treatment.
Steroid-refractory GVHDwas deﬁned as histologically conﬁrmed disease
not clinically responding to standard steroid therapy (2  1 mg/kg for
intestinal GVHD combined with mycophenolate mofetil 2  1 g/day) and
requiring second-line salvage immunosuppressive therapy, usually pen-
tostatin [14]. Further attempts at salvage therapy were individualized and
included mesenchymal stem cells, tacrolimus, basiliximab, rituximab, and
inﬂiximab.
Serum Samples, ELISA, and Multiplex Analysis
Serum samples were collected before allo-SCT and thereafter at weekly
or biweekly intervals for a maximum of 1 year. After sample collection,
serum was immediately obtained by centrifugation, transferred into cry-
otubes, and stored at -80C until further processing. sTM was measured by
ELISA (Diaclone, Besancon, France) as described previously [9]. Concentra-
tions of ANG2, IL-8, and HGF were quantiﬁed by Luminex multiplex protein
array technology according to the manufacturer’s instructions for protein
multiplexing (BioRad, Hercules, CA), as described previously [9].
Statistical Analysis
Categorical data on patient characteristics at the time of allo-SCT were
compared using Fisher’s exact test. The distributions of age attransplantation and time to onset of GVHD were compared with respect to
GVHD grade using the Kruskal-Wallis test. Serum parameters (sTM, ANG2,
IL-8, and HGF) were measured in samples obtained before and on
days þ50 and þ100 after allo-SCT. Pairwise comparisons of serum marker
levels with respect to GVHD grade were performed using Wilcoxon’s rank
sum test. Serum levels of endothelial stress markers at different
measurement time points (before SCT and at days þ50 and þ100 after
SCT) were compared within each group using Friedman’s test, as deﬁned
in Table 1.
Overall survival (OS) was calculated as the time from day þ50 or þ100
after allo-SCT to death from any cause. NRMwas calculated as the time from
day þ50 or þ100 after allo-SCT to the endpoint of death in the absence of
relapse, with recurrence of the underlying malignancy as the competing
event. For the landmark analysis at days þ50 and þ100 after allo-SCT,
patients who experienced a GVHD episode before day þ50 or day þ100
were classiﬁed as no GVHD, grade I-II GVHD, steroid-sensitive grade III-IV
GVHD, or steroid-refractory grade III-IV GVHD. The log-rank test was used
to compare these groups with respect to OS, and Gray’s test [15] was used for
comparisons with respect to NRM.
Serum parameters were also analyzed for prediction of NRM using
univariate proportional subdistribution hazards regression models [16,17].
A multivariate proportional subdistribution hazards regression model
was performed at days þ50 and þ100 to adjust the impact of serum
parameters (sTM, ANG2, IL-8, and HGF) on NRM for the potential
confounders donor, conditioning regimen, age, and disease-speciﬁc
remission score.
Calculations were done using R version 2.13.2, with the R packages coin
version 1.0-19, rms version 3.3-0, cmprsk version 2.2-2, and kmi version 0.3-
4 (R Foundation for Statistical Computing, Vienna, Austria), or MedCalc
version 11.1 (MedCalc Software, Mariakerke, Belgium). All statistical tests
were 2-sided, with a P value <.05 considered to indicate a statistically
signiﬁcant result.
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Figure 1. Median levels of endothelial serum parameters ANG2 (A), sTM (B), IL-8 (CXCL8) (C), and HGF (D) measured before allo-SCT and on days þ50 and þ100 after
allo-SCT. Serum samples obtained posttransplantation were available for 331 patients, at day þ50 after allo-SCT in 297 patients, and at day þ100 after allo-SCT in 300
patients. ANG2 was elevated in steroid-refractory patients before allo-SCT compared with patients with sensitive grade III-IV GVHD (P < .03, refractory grade III-IV
versus sensitive grade III-IV; P < .05, refractory grade III-IV versus sensitive grade I-II; Wilcoxon’s rank sum test), but did not differ compared with those with low-
grade GVHD or no GVHD. No signiﬁcant pretransplantation differences in the other parameters (IL-8, HGF, and sTM) were detected. On days þ50 and þ100, sTM, IL-8
(CXCL8), and HGF levels were signiﬁcantly higher in patients with refractory grade III-IV GVHD compared with those in all other groups (P < .05).
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Patient Characteristics
Of the 608 patients who underwent allo-SCT in our
institution between 2001 and 2010, 404 met the eligi-
bility criteria for the present study. Of these 404
patients, 177 (44%) experienced at least 1 episode of
acute GVHD. The patients were categorized into 4
groups based on the course of their most severe GVHD
episode: group 1 (n ¼ 227), patients without any acute
GVHD; group 2 (n ¼ 98), patients with steroid-sensitive
acute GVHD grade I-II; group 3 (n ¼ 35), patients with
steroid-sensitive acute GVHD grade III-IV; and group 4
(n ¼ 44), patients with steroid-refractory acute GVHD
(which was always grade III-IV at its maximum severity).
Thirty-ﬁve patients with high-grade GVHD were part of
our previous study [9]; the other 13 patients from our
previous study could not be included because they had
no available serum samples.
Baseline transplant- and disease-speciﬁc variables of the
4 study groups are summarized in Table 1. Generally, these
characteristics did not differ signiﬁcantly among the groups,except for donorerecipient HLA mismatch and site of GVHD.
There was no signiﬁcant difference in the site of GVHD
manifestations between patients with steroid-sensitive
grade III-IV GVHD (group 3) and those with steroid-
refractory grade III-IV GVHD (group 4).
Increased NRM and Reduced OS Only in Patients with
Acute Steroid-Refractory Grade III-IV GVHD
Two-year NRM exceeded 70% in patients with steroid-
refractory grade III-IV GVHD at both landmarks but was
below 20% in GVHD groups 1-3 (P < .0001) (Supplemental
Figure 1A). Similarly, OS was reduced in patients with
refractory GVHD, but not in those with steroid-sensitive
grade I-IV GVHD compared with patients without GVHD
(P < .001) (Supplemental Figure 1B).
At day þ50, 28% of patients had developed acute GVHD,
6% with steroid-refractory disease. At day þ100, 38% of
patients had developed acute GVHD, 8% with steroid-
refractory disease. Beyond day þ100, only 7% of patients
developed acute GVHD, and only 3% had steroid-refractory
GVHD. Time to onset of GVHD did not differ among
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Figure 2. Cumulative incidence of NRM in patients with low ANG2 levels (<1000 pg/mL) and high ANG2 levels (>1000 pg/mL) measured before allo-SCT, calculated
using Gray’s test. (A) All patients. (B) Patients with grade I-II GVHD. (C) Patients with grade III-IV GVHD.
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(grade II-IV), and those with sensitive and high-grade
refractory disease (Table 1).
Rise in Endothelial Stress Markers after Transplantation
The kinetics of the endothelial damage markers ANG2,
IL-8 (CXCL8), HGF, and sTM levels were compared among
patients of the 4 groups (Table 1). Starting from similar
levels in the 4 groups, sTM rose in all groups during the
early posttransplantation period (P < .01), but the rise was
strongest in the steroid-refractory patients (grade III-IV
sensitive versus grade III-IV refractory at days þ50
and þ100: P < .01) (Figure 1B). IL-8 (CXCL8) and HGF rose
only in patients with steroid-refractory GVHD during the
posttransplantation period (days þ50 and þ100; all P < .05)
(Figure 1C and D). ANG2 levels differed only between
patients with high-grade sensitive GVHD and those with
refractory GVHD (see below). No differences in ANG-2 levels
at the different sites of GVHD manifestation (ie, liver, skin, or
gut) were seen at any time point.
Pretransplantation ANG2 Level Predictive of GVHD
Refractoriness Only in Patients with High-Grade GVHD
Serum ANG2 levels were elevated before transplantation
and on day þ50 in patients with acute refractory grade III-IV
GVHD compared with those with acute sensitive grade III-IV
GVHD (Figure 1A). In contrast, there was no difference ofpretransplantation ANG2 levels between patients without
GVHD and those with grade III-IV GVHD. Accordingly, when
all patients for whom serum samples were available were
considered, high levels of ANG2 (ANG2 > 1000 pg/mL) was
not predictive of the development of refractory GVHD
(odds ratio [OR], 1.8, 95% CI, 0.7-4.5; P ¼ .20). Likewise, ANG2
levels measured before transplantation were not predictive
of any grade I-II or grade III-IV GVHD (OR, 0.7; 95% CI, 0.4-1.2;
P ¼ .20). However, when the analysis was restricted to
those patients who later developed grade III-IV acute GVHD,
high pretransplantation ANG2 levels were predictive of
nonresponse to high-dose steroid therapy (OR, 3.9; 95%
CI, 1.3-12.0; P ¼ .01). The same ﬁnding applied for NRM
rates, with no association between high pretransplantation
ANG2 levels and increased NRM (Figure 2A,B). In contrast,
high ANG2 levels before transplantation were predictive of
signiﬁcantly increased NRM in the subset of patients who
developed severe high-grade GVHD (HR, 6.0; 95% CI, 2.4-
14.8; P ¼ .01) (Figure 2C).
To rule out the possibility that different outcomes in
patients with grade III-IV GVHD and low (<1000 pg/mL) or
high (<1000 pg/mL) ANG-2 levels are a consequence of
unevenly distributed baseline and transplantation charac-
teristics, we compared the 2 groups in terms of age, sex,
disease type, disease-speciﬁc remission score, donor, condi-
tioning, donorerecipient sex match, and stem cell source,
and found no signiﬁcant differences (Supplemental Table 1).
Table 2
Multivariate Analysis of Endothelial Stress Markers and Transplantation-Related Baseline Variables in Terms of NRM Calculated at Days þ50 and þ100 after
Allo-SCT
Covariate Effect NRM at Day þ50 NRM at Day þ100
P Value HR (95% CI) P Value HR (95% CI)
Age þ10 years .03 1.8 (1.2-2.9) .02 1.9 (1.3-2.9)
Conditioning RIC versus MAC .12 0.5 (0.2-1.2) .13 1.1 (0.3-3.8)
Donor RD versus MUD .25 0.5 (0.2-1.5) .28 1.7 (0.6-4.8)
RD versus MMUD .55 1.3 (0.5-3.8) .02 3.3 (1.2-3.3)
Disease score [29] 0 versus 1 .30 0.3 (0.1-2.9) .71 0.7 (0.2-4.7)
0 versus 2 .54 1.3 (0.6-3.1) .25 1.6 (0.7-6.2)
ANG2 þ1 ng .013 1.3 (1.1-1.6) .003 1.3 (1.1-1.6)
IL-8 þ25 pg .09 1.1 (0.9-1.2) .02 1.2 (1.1-1.3)
HGF þ1 ng .98 1.4 (0.3-1.8) .29 1.4 (0.3-1.8)
sTM þ5 pg <.001 1.1 (1.0-1.2) <.001 1.1 (1.0-1.2)
MUD indicates matched unrelated donor; MMUD, mismatched unrelated donor; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning.
Age and endothelial stress markers were measured as continuous variables.
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(ANG2>1000 pg/mL) were associated with higher serum
levels of IL-8 (CXCL8) (P < .05) and HGF (P < .01) on
days þ50 and þ100 posttransplantation, suggesting that the
3 endothelial markers are correlated and deﬁne a speciﬁc
patient cohort.
Endothelial Stress Markers Predictive of NRM at Day þ50
and Day þ100 Landmarks
On univariate comparisons, both sTM and IL-8 (CXCL8)
measured on days þ50 and þ100 were signiﬁcantly predic-
tive of NRM (sTM day þ50: HR, 1.5 per 5-pg increase [95% CI,
1.2-1.7], P < .001; sTM day þ100: HR, 1.8 per 5-pg increase
[95% CI, 1.5-2.1], P < .001; IL-8 day þ 50: HR, 1.1 per 25-pg
increase [95% CI, 1.0-1.2], P ¼ .05; IL-8 day þ100: HR, 1.2
per 25-pg increase [95% CI, 1.1-1.3]; P ¼ .004). Increased
ANG2 levels were signiﬁcantly associated with higher NRM
only on day þ50 (day þ50: HR, 1.2 per 1-ng/mL increase
[95% CI, 1.1-1.4], P < .0001; day þ100: HR, 1.1 per 1-ng/mL
increase [95% CI 0.9-1.2], P¼ .20). No signiﬁcant effect of HGF
levels on NRM was observed (day þ50: HR 1.0 [95% CI,
0.9-1.1], P < .65; day þ100: HR, 1.0 [95% CI, 0.9-1.1], P < .91).
On multivariate analyses adjusting for age, conditioning
(myeloablative versus reduced intensity), donor and disease-
speciﬁc remission score, sTM and ANG2 levels were
conﬁrmed to be statistically signiﬁcant prognostic factors for
NRM at both the dayþ50 and dayþ100 landmarks (Table 2).
IL-8 (CXCL8) was signiﬁcantly predictive for NRM at
day þ100, but only borderline signiﬁcantly predictive for
NRM at day þ50 (Table 2). In addition, older age at both
landmarks and receipt of a mismatched unrelated donor
transplant at the day þ100 landmark were signiﬁcantly
associated with NRM (Table 2).
DISCUSSION
The present study supports the hypothesis that endo-
thelial vulnerability is involved in the pathogenesis of
refractory GVHD. We extended the analyses of our previous
report to a larger group of patients with severe GVHD, and
included all eligible patients with low-grade or no GVHD.We
studied ANG2 and sTM kinetics as markers of endothelial cell
dysfunction [10,18,19]. Furthermore, we evaluated IL-8
(CXCL8) and HGF, 2 additional markers of endothelial stress
[10-12].
After allo-SCT, sTM levels rose signiﬁcantly in all patients
at days þ50 and þ100, likely reﬂecting toxicity mediated by
calcineurin inhibitors. This was not the case in our previous
study, in which we found a signiﬁcant sTM increase only inpatients with refractory GVHD. This discrepancy might be
explained by a much smaller number of patients and
a different sampling schedule in the previous study [9]. Of
note, and in accordance with our previous study, the patients
with refractory GVHD in the present study had much higher
posttransplantation sTM levels compared with all other
groups, and sTM was highly predictive of NRM. Similarly, 2
additional endothelial stress markers, IL-8 (CXCL8) and HGF,
were increased only in patients with refractory GVHD post-
transplantation. IL-8 (CXCL8) and HGF are both endothelial-
derived, hypoxia-induced growth factors that can be
measured in increased serum concentrations during endo-
thelial stress and in disorders associated with endothelial
damage, such as hypertension, stroke, and hypercoagula-
bility [11,13,20]. HGF and IL-8 (CXCL8) have been shown to
predict outcome of GVHD at disease onset [21-23]. Impor-
tantly, the endothelial stress markers ANG-2, IL-8, and sTM
were independent predictors of NRM on daysþ50 andþ100,
further supporting the relevance of endothelial damage after
transplantation.
In contrast with their predictive value on days þ50
and þ100 after allo-SCT, none of the 4 endothelial stress
markers was signiﬁcantly associated with refractory GVHD
or NRM in the large patient cohort when measured before
allo-SCT. Nonetheless, pretransplantation ANG2 serum levels
were signiﬁcantly higher in patients who later developed
refractory GVHD compared with those who developed high-
grade but sensitive GVHD. ANG2 level also predicted NRM in
the group of patients who later developed grade III-IV GVHD.
Pretransplantation ANG2 level did not signiﬁcantly predict
refractory GVHD when all patients were analyzed, implying
that ANG2might not be a relevant factor for predicting GVHD
risk. Instead, our ﬁndings suggest that endothelial vulnera-
bility (as indicated by high pretransplantation ANG2 level)
becomes important only if the patient actually experiences
a severe GVHD episode. The ensuing inﬂammation might
preferentially damage endothelial cells exposed to high
ANG2 concentration. In the absence of GVHD, however, this
vulnerability would not achieve clinical relevance. In this
context, it is noteworthy that pretransplantation ANG2 levels
were correlated with higher posttransplantation IL-8
(CXCL8) and HGF levels, supporting the hypothesis that
these markers deﬁne patients with endothelial vulnerability.
There is now accumulating evidence that vascularization
and endothelial function play important roles in the
pathogenesis of GVHD [24-28]. Although ANG2 is a prom-
ising candidate marker for estimating the risk of refractory
disease if GVHD develops, various additional variables may
S. Dietrich et al. / Biol Blood Marrow Transplant 19 (2013) 22e27 27contribute to endothelial vulnerability as well. Under-
standing the origin of deviant endothelial stress responses in
patients with steroid-refractory GVHD is crucial for the
design of interventional treatment strategies targeting
endothelial dysfunction.
In conclusion, our data add to the evidence that endo-
thelial cell damage plays an important role in the patho-
genesis of steroid-refractoriness of ongoing GVHD, but
suggest that it does not necessarily contribute to the risk of
developing GVHD per se. Thus, the measurement of pre-
transplantation markers of endothelial vulnerability, such as
ANG2, could help determine the individual transplantation
strategy (eg, intensity of immunosuppression) in patients
with at high risk for GVHD (eg, recipients of mismatched
transplants). However, additional studies of the biological
causes of endothelial vulnerability are needed to better
assess the individual risk of allo-SCT, optimize post-
transplantation management, and prevent steroid-refractory
courses of GVHD.
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